One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults ...

UCB, a global biopharmaceutical company, today announced new data in moderate-to-severe plaque psoriasis (PSO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, March 27–31.

Rising prices during the Ukraine energy crisis in 2022 and 2023 are still fresh in people's minds. When bills went through the roof, it drove the first wave of solar deployment.

EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for ...

Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety ...

As cities worldwide accelerate toward electrification and decarbonization, the convergence of distributed energy resources and electric mobility is ...

The Pakistan Stock Exchange (PSX) observed selling pressure on Thursday, with the KSE-100 Index shedding nearly 5,000 points ...

T he recent reimbursement of Bimzelx (bimekizumab) in Ireland represents an important step forward in access to treatment for ...

ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety ...

ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated wit ...